RESUMO
Salicylic acid-induced protein kinase (SIPK) is known as a 'master switch' for stress responses in plants. It can be induced by salicylic acid (SA) and several stress factors. The main aim of the present study was to reveal the relationship between SA accumulation and the gene expression level of SIPK during 50 and 250 µm Cd stress in wheat plants. Quantitative real-time PCR was used for determination of the gene expression level of SIPK. Salicylic acid content measurement was performed with an HPLC system equipped with a fluorescence detector. Cadmium treatment increased the endogenous SA level and expression level of SIPK in a concentration-dependent manner. Induction of SIPK expression preceded the accumulation of endogenous SA. Although SA treatment induced dramatic endogenous SA accumulation, its SIPK-inducing effect was moderate. In roots, higher induction of SIPK was observed than in leaves. The same tendency of SIPK expression was observed in both Cd- and SA-treated plants, as decisively the highest transcript level was detected after 30 min of treatment, but thereafter the expression decreased rapidly to control level or even below. The induction of SIPK was transient in all cases, and even a very high SA level in either the leaves or roots was not able to maintain the elevated expression level of this gene. The results suggest that SIPK has a role in initiating Cd stress response and the exogenous SA-induced signalling process.
Assuntos
Cádmio/toxicidade , Ácido Salicílico/farmacologia , Triticum/efeitos dos fármacos , Triticum/metabolismo , Proteínas Quinases/metabolismoRESUMO
BACKGROUND: Migraine is a debilitating neurological disorder where trigeminovascular activation plays a key role. We have previously reported that local application of Complete Freund's Adjuvant (CFA) onto the dura mater caused activation in rat trigeminal ganglion (TG) which was abolished by a systemic administration of kynurenic acid (KYNA) derivate (SZR72). Here, we hypothesize that this activation may extend to the trigeminal complex in the brainstem and is attenuated by treatment with SZR72. METHODS: Activation in the trigeminal nucleus caudalis (TNC) and the trigeminal tract (Sp5) was achieved by application of CFA onto the dural parietal surface. SZR72 was given intraperitoneally (i.p.), one dose prior CFA deposition and repeatedly daily for 7 days. Immunohistochemical studies were performed for mapping glutamate, c-fos, PACAP, substance P, IL-6, IL-1ß and TNFα in the TNC/Sp5 and other regions of the brainstem and at the C1-C2 regions of the spinal cord. RESULTS: We found that CFA increased c-fos and glutamate immunoreactivity in TNC and C1-C2 neurons. This effect was mitigated by SZR72. PACAP positive fibers were detected in the fasciculus cuneatus and gracilis. Substance P, TNFα, IL-6 and IL-1ß immunopositivity were detected in fibers of Sp5 and neither of these molecules showed any change in immunoreactivity following CFA administration. CONCLUSION: This is the first study demonstrating that dural application of CFA increases the expression of c-fos and glutamate in TNC neurons. Treatment with the KYNA analogue prevented this expression.
Assuntos
Dura-Máter/efeitos dos fármacos , Dura-Máter/metabolismo , Adjuvante de Freund/administração & dosagem , Ácido Glutâmico/biossíntese , Ácido Cinurênico/análogos & derivados , Proteínas Proto-Oncogênicas c-fos/biossíntese , Administração Tópica , Animais , Adjuvante de Freund/toxicidade , Regulação da Expressão Gênica , Ácido Cinurênico/administração & dosagem , Masculino , Transtornos de Enxaqueca/induzido quimicamente , Transtornos de Enxaqueca/metabolismo , Transtornos de Enxaqueca/prevenção & controle , Ratos , Ratos Sprague-DawleyRESUMO
BACKGROUND: Neurogenic inflammation has for decades been considered an important part of migraine pathophysiology. In the present study, we asked the question if administration of a novel kynurenic acid analogue (SZR72), precursor of an excitotoxin antagonist and anti-inflammatory substance, can modify the neurogenic inflammatory response in the trigeminal ganglion. METHODS: Inflammation in the trigeminal ganglion was induced by local dural application of Complete Freunds Adjuvant (CFA). Levels of phosphorylated MAP kinase pERK1/2 and IL-1ß expression in V1 region of the trigeminal ganglion were investigated using immunohistochemistry and Western blot. FINDINGS: Pretreatment with one dose of SZR72 abolished the CFA-induced pERK1/2 and IL-1ß activation in the trigeminal ganglion. No significant change was noted in case of repeated treatment with SZR72 as compared to a single dose. CONCLUSIONS: This is the first study that demonstrates that one dose of KYNA analog before application of CFA can give anti-inflammatory response in a model of trigeminal activation, opening a new line for further investigations regarding possible effects of KYNA derivates.
Assuntos
Anti-Inflamatórios/uso terapêutico , Adjuvante de Freund/toxicidade , Interleucina-1beta/biossíntese , Ácido Cinurênico/análogos & derivados , Sistema de Sinalização das MAP Quinases/fisiologia , Gânglio Trigeminal/metabolismo , Animais , Anti-Inflamatórios/farmacologia , Regulação da Expressão Gênica , Inflamação/induzido quimicamente , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Interleucina-1beta/antagonistas & inibidores , Ácido Cinurênico/farmacologia , Ácido Cinurênico/uso terapêutico , Masculino , Ratos , Ratos Sprague-Dawley , Gânglio Trigeminal/efeitos dos fármacos , Gânglio Trigeminal/patologiaRESUMO
BACKGROUND: The trigeminal ganglion (TG) plays a central role in cranial pain. Administration of complete Freund's adjuvant (CFA) into the temporomandibular joint (TMJ) elicits activation of TG. Kynurenic acid (KYNA) is an endogenous excitatory amino acid receptor blocker, which may have an anti-inflammatory effect. We hypothesize that KYNA may reduce CFA-induced activation within the TG. METHODS: A local inflammation was induced by administration of CFA into the TMJ in rats. KYNA and kynurenic acid amide 2 (KYNAA2) were intraperitoneally administered. We investigated changes of mitogen-activated protein kinases (MAPKs as ERK1/2, p38 and SAPK/JNK), NF-κB, CaMKII and DREAM, in addition to calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in the TG, with immunohistochemistry and Western blot at 2 and 10 days post-CFA injection. RESULTS: We showed CFA-induces increases in pERK1/2, pp38, CaMKII, NF-κB and DREAM immunohistochemistry after 2 and 10 days. KYNAA2 displayed stronger effects on MAPKs than KYNA. Increased expression of CaMKII, NF-κB and DREAM were found in the neurons. Western blot showed significantly increase in pERK expression at 10 days post-CFA, which decreased after 10 days of KYNA treatment. Two days post-CFA, a significantly increase in pp38 expression was found, which decreased after 2 days of KYNA and KYNAA2 treatment. CONCLUSIONS: The CFA-induced inflammatory model for the TG activation provided a time-related expression of MAPK (pERK1/2, pp38) and NF-κB. It involves both the neuronal and glial activation, which points to possible neuron-glia interactions during this process. The administration of the endogenous NMDA-receptor antagonists, KYNA and its derivative KYNAA2, resulted in the inhibition of the induced signaling system of the TG, which further points the importance of the glutamate receptors in this mechanism.
Assuntos
Antagonistas de Aminoácidos Excitatórios/farmacologia , Inflamação/tratamento farmacológico , Ácido Cinurênico/farmacologia , Gânglio Trigeminal/efeitos dos fármacos , Adjuvantes Imunológicos/toxicidade , Animais , Biomarcadores/metabolismo , Western Blotting , Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Modelos Animais de Doenças , Adjuvante de Freund/toxicidade , Inflamação/metabolismo , Masculino , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Ratos , Ratos Sprague-Dawley , Transdução de Sinais/efeitos dos fármacos , Gânglio Trigeminal/metabolismo , eIF-2 Quinase/metabolismoRESUMO
BACKGROUND: Migraine is a painful disorder with a huge impact on individual and public health. We hypothesize that migraine pain originates from a central mechanism that results secondarily in hypersensitivity in peripheral afferents associated with the cerebral and cranial blood vessels. It has previously been shown that application of inflammatory or algesic substances onto the dura mater or chemical stimulation of the dural receptive fields causes hypersensitivity to mechanical and thermal stimulation together with direct activation of the TG. We asked whether local inflammation of dura mater induces inflammatory activation in the trigeminal ganglion. METHODS: We performed topical administration of inflammatory soup (IS) or Complete Freund's Adjuvant (CFA) onto an exposed area of the rat dura mater in vivo for 20 min. The window was closed and the rats were sacrificed after 4 h and up to 7 days. Myography was performed on middle meningeal arteries. The trigeminal ganglia were removed and processed for immunohistochemistry or Western blot. RESULTS: Both CFA and IS induced enhanced expression of pERK1/2, IL-1ß and CGRP in the trigeminal ganglia. The pERK1/2 immunoreactivity was mainly seen in the satellite glial cells, while IL-1ß reactivity was observed in the neuronal cytoplasm, close to the cell membrane, seemingly as sign of neuro-glial interaction. The CGRP expression in the neurons and nerve fibres was enhanced after the application of either inflammatory agent. Myography resulted in a strong vasoconstrictor response to IS, but not to CFA. CONCLUSIONS: These results suggest that the application of IS or CFA onto the dura mater causes long-term activation of the TG and demonstrate the importance of the neuro-glial interaction in the activation of the trigeminovascular system.
Assuntos
Dura-Máter/metabolismo , Adjuvante de Freund/administração & dosagem , Adjuvante de Freund/toxicidade , Mediadores da Inflamação/metabolismo , Gânglio Trigeminal/metabolismo , Animais , Dura-Máter/efeitos dos fármacos , Inflamação/induzido quimicamente , Inflamação/metabolismo , Masculino , Transtornos de Enxaqueca/induzido quimicamente , Transtornos de Enxaqueca/metabolismo , Fibras Nervosas/efeitos dos fármacos , Fibras Nervosas/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Dor/induzido quimicamente , Dor/metabolismo , Ratos , Ratos Sprague-Dawley , Gânglio Trigeminal/efeitos dos fármacosRESUMO
The interaction between kynurenic acid (KYNA) and two peptide fragments (ca. 30 residues) of Human Glutamate Receptor 201-300 (GluR1) using surface plasmon resonance (SPR) spectroscopy was investigated. Because of the medical interest in the neuroscience, GluR1 is one of the important subunits of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR). AMPARs are ionotoropic glutamate receptors, which are mediating fast synaptic transmission and are crucial for plasticity in the brain. On the other hand, KYNA has been suggested to have neuroprotective activity and it has been considered for apply in therapy in certain neurobiological disorders. In this article the adsorption of the GluR1201-230 and GluR1231-259 peptides were studied on gold biosensor chip. The peptides were chemically bonded onto the gold surface via thiol group of L-cysteine resulted in the formation of peptide monolayer on the SPR chip surface. Because the GluR1231-259 peptide does not contain L-cysteine the Val256 was replaced by Cys256. The cross sectional area and the surface orientation of the studied peptides were determined by SPR and theoretical calculations (LOMETS) as well. The binding capability of KYNA on the peptide monolayer was studied in the concentration range of 0.1-5.0 mM using 150 mM NaCl ionic strength at pH 7.4 (±0.02) in phosphate buffer solutions. In order to determine the binding enthalpy the experiments were carried out between +10°C and +40°C. The heat of adsorption was calculated by using adsorption isotherms at different surface loading of KYNA on the SPR chip.
Assuntos
Ácido Cinurênico/química , Fragmentos de Peptídeos/química , Receptores de Glutamato/química , Ressonância de Plasmônio de Superfície/métodos , Adsorção , Humanos , Ligação ProteicaRESUMO
Migraine is a common, paroxysmal, highly disabling primary headache disorder. The origin of migraine attacks is enigmatic. Numerous clinical and experimental results suggest that the activation of distinct brainstem nuclei is crucial in its pathogenesis, but the primary cause of this activation is not fully understood. We conclude that the initialization of a migraine attack can be explained as an altered function of the neuronal elements of the brainstem nuclei. In light of our findings and the literature data, we can assume that migraine is a subcortical disorder of a specific brainstem area.
Assuntos
Tronco Encefálico/fisiopatologia , Transtornos de Enxaqueca/fisiopatologia , Animais , Humanos , Transtornos de Enxaqueca/tratamento farmacológico , Transtornos de Enxaqueca/metabolismo , Vias Neurais/fisiopatologiaRESUMO
Cranial parasympathetic outflow is mediated through the sphenopalatine ganglion (SPG). The present study was performed to examine the expression of the parasympathetic signaling transmitters and their receptors in human and rat SPG. Indirect immunofluorescence technique was used for the demonstration of vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), nitric oxide synthase (NOS), glutamine synthetase (GS), glial fibrillary acidic protein (GFAP), VIP and PACAP common receptors (VPAC1, VPAC2), and PACAP receptor (PAC1). In addition, double labeling was carried out to reveal the co-localization of neurotransmitters. VIP-immunoreactive (-ir) neurons as well as fibers were frequently found in human SPG. Many, homogenously stained NOS-ir cells were found, but no positive fibers. In addition, PACAP-ir was observed in some of the neurons and in fibers. Co-localization was found between VIP and NOS. In rat VIP-, NOS-, and PACAP-ir were found in many neurons and fibers. Co-localization of PACAP and NOS was observed in neurons. PACAP and GS double staining revealed that the PACAP-ir was localized in/close to the cell membrane, but not in the satellite glial cells. PAC1 and VPAC1 immunoreactivity was found in the satellite glial cells of both human and rat. Western blot revealed protein expression of PAC1, VPAC1, and VPAC2 in rat SPG. The trigeminal-autonomic reflex may be active in migraine attacks. We hypothesized that VIP, PACAP, NOS, PAC1, VPAC1, and VPAC2 play a role in the activation of parasympathetic cranial outflow during migraine attacks.
Assuntos
Gânglios Parassimpáticos/metabolismo , Óxido Nítrico Sintase/metabolismo , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/metabolismo , Receptores de Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/metabolismo , Receptores de Peptídeo Intestinal Vasoativo/metabolismo , Peptídeo Intestinal Vasoativo/metabolismo , Idoso , Idoso de 80 Anos ou mais , Animais , Western Blotting , Cadáver , Corantes , Feminino , Fluoresceína-5-Isotiocianato , Corantes Fluorescentes , Gânglios Parassimpáticos/citologia , Proteína Glial Fibrilar Ácida/metabolismo , Humanos , Processamento de Imagem Assistida por Computador , Imuno-Histoquímica , Masculino , Neurônios/metabolismo , Ratos , Ratos Sprague-Dawley , Rodaminas , Especificidade da EspécieRESUMO
Migraine is a common, paroxysmal, highly disabling primary headache disorder with a genetic background. The primary cause and the origin of migraine attacks are enigmatic. Numerous clinical and experimental results suggest that activation of the trigeminal system (TS) is crucial in its pathogenesis, but the primary cause of this activation is not fully understood. Since activation of the peripheral and central arms of the TS might be related to cortical spreading depression and to the activity of distinct brainstem nuclei (e.g. the periaqueductal grey), we conclude that migraine can be explained as an altered function of the neuronal elements of the TS, the brainstem, and the cortex, the centre of this process comprising activation of the TS. In light of our findings and the literature data, therefore, we can assume that migraine is mainly a neuronal disease.
Assuntos
Tronco Encefálico/fisiopatologia , Córtex Cerebral/fisiopatologia , Transtornos de Enxaqueca/fisiopatologia , Rede Nervosa/fisiopatologia , Nervo Trigêmeo/fisiopatologia , Animais , Tronco Encefálico/metabolismo , Peptídeo Relacionado com Gene de Calcitonina/fisiologia , Córtex Cerebral/metabolismo , Depressão Alastrante da Atividade Elétrica Cortical/fisiologia , Ácido Glutâmico/fisiologia , Humanos , Ácido Cinurênico/metabolismo , Transtornos de Enxaqueca/metabolismo , Rede Nervosa/metabolismo , Substância Cinzenta Periaquedutal/metabolismo , Substância Cinzenta Periaquedutal/fisiopatologia , Nervo Trigêmeo/metabolismo , Núcleos do Trigêmeo/metabolismo , Núcleos do Trigêmeo/fisiopatologiaRESUMO
Calcitonin gene related peptide (CGRP) has a key role in migraine and recently CGRP receptor antagonists have demonstrated clinical efficacy in the treatment of migraine. However, it remains unclear where the CGRP receptors are located within the CGRP signaling pathway in the human trigeminal system and hence the potential antagonist sites of action remain unknown. Therefore we designed a study to evaluate the localization of CGRP and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein (RAMP) 1 in the human trigeminal ganglion using immunohistochemistry and compare with that of rat. Antibodies against purified CLR and RAMP1 proteins were produced and characterized for this study. Trigeminal ganglia were obtained at autopsy from adult subjects and sections from rat trigeminal ganglia were used to compare the immunostaining pattern. The number of cells expressing CGRP, CLR and RAMP1, respectively, were counted. In addition, the glial cells of trigeminal ganglion, particularly the satellite glial cell, were studied to understand a possible relation. We observed immunoreactivity for CGRP, CLR and RAMP1, in the human trigeminal ganglion: 49% of the neurons expressed CGRP, 37% CLR and 36% RAMP1. Co-localization of CGRP and the receptor components was rarely found. There were no CGRP immunoreactions in the glial cells; however some of the glial cells displayed CLR and RAMP1 immunoreactivity. Similar results were observed in rat trigeminal ganglia. We report that human and rat trigeminal neurons store CGRP, CLR and RAMP1; however, CGRP and CLR/RAMP1 do not co-localize regularly but are found in separate neurons. Glial cells also contain the CGRP receptor components but not CGRP. Our results indicate, for the first time, the possibility of CGRP signaling in the human trigeminal ganglion involving both neurons and satellite glial cells. This suggests a possible site of action for the novel CGRP receptor antagonists in migraine therapy.
Assuntos
Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Proteína Semelhante a Receptor de Calcitonina/metabolismo , Proteína 1 Modificadora da Atividade de Receptores/metabolismo , Gânglio Trigeminal/metabolismo , Idoso , Idoso de 80 Anos ou mais , Animais , Anticorpos/isolamento & purificação , Proteína Semelhante a Receptor de Calcitonina/imunologia , Contagem de Células , Linhagem Celular , Feminino , Humanos , Imuno-Histoquímica , Masculino , Neuroglia/metabolismo , Neurônios/metabolismo , Ratos , Ratos Sprague-Dawley , Proteína 1 Modificadora da Atividade de Receptores/imunologiaRESUMO
Hydrosoluble diclofenac epolamine (DHEP) represents an interesting approach to acute migraine attacks, where gastrointestinal motility and drug absorption are often reduced. Its efficacy was investigated in a randomized, crossover, double-blind trial on 155 patients who treated four consecutive mild-to-moderate migraine attacks, either with DHEP (65-mg sachet) or placebo. If pain was not relieved within 1 h, a second dose was given. The total number of treated attacks was 481. A pain-free condition was achieved within 2 h in 45.8% and 25.1% of attacks treated, respectively, with DHEP or placebo (P < 0.0001), with a therapeutic gain of 20.7%. Time to attack resolution, light and noise sensitivity and impact on working ability were significantly reduced by DHEP compared with placebo. Moreover, significantly fewer patients required a second drug dose or a rescue medication when treated with DHEP than with placebo. No adverse reaction was recorded. In conclusion, DHEP was effective and safe for pain relief in patients with an acute mild-to-moderate migraine attack.
Assuntos
Diclofenaco/administração & dosagem , Transtornos de Enxaqueca/tratamento farmacológico , Transtornos de Enxaqueca/epidemiologia , Medição da Dor/efeitos dos fármacos , Adulto , Analgésicos/administração & dosagem , Método Duplo-Cego , Europa (Continente) , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Efeito Placebo , Resultado do TratamentoRESUMO
Neurovascular compression (NC) seems to have been confirmed as the major cause of classical trigeminal neuralgia (TN). In spite of the large number of surgically positive cases, however, there are still cases where no vascular compression of the trigeminal nerve can be found. To evaluate whether NC could be demonstrated preoperatively, high-resolution magnetic resonance angiography (MRA) was performed in 287 consecutive patients with TN and persistent idiopathic facial pain (PIFP) on a 0.5-T and a 1-T MR unit. Depending on the clinical symptoms, the TN cases were divided into typical TN and trigeminal neuralgia with non-neuralgic interparoxysmal pain (TNWIP) groups. Microvascular decompression (MVD) was performed in 103 of the MRA-positive cases. The patients were followed up postoperatively for from 1 to 10 years. The clinical symptoms were compared with the imaging results. The value of MRA was assessed on the basis of the clinical symptoms and surgical findings. The outcome of MVD was graded as excellent, good or poor. The clinical symptoms were compared with the type of vascular compression and the outcome of MVD. The MRA image was positive in 161 (56%) of the 287 cases. There were significant differences between the clinical groups: 66.5% of the typical TN group, 47.5% of the TNWIP group and 3.4% of the PIFP group were positive. The quality of the MR unit significantly determined the ratio of positive/negative MRA results. The surgical findings corresponded with the MRA images. Six patients from the MRA-negative group were operated on for selective rhizotomy and no NC was found. Venous compression of the trigeminal nerve was observed in a significantly higher proportion in the background of TNWIP than in that of typical TN on MRA imaging (24.1% and 0.8%, respectively) and also during MVD (31.2% and 1.2%, respectively). Four years following the MVD, 69% of the patients gave an excellent, 23% a good and 8% a poor result. The rate of some kind of recurrence of pain was 20% in the typical TN and 44% in TNWIP group. The rate of recurrence was 57% when pure venous compression was present. The only patient who was operated on from the PIFP group did not react to the MVD. The clinical symptoms and preoperative MRA performed by at least a 1-T MR unit furnish considerable information, which can play a role in the planning of the treatment of TN.
Assuntos
Descompressão Cirúrgica , Dor Facial/diagnóstico por imagem , Dor Facial/cirurgia , Angiografia por Ressonância Magnética , Neuralgia do Trigêmeo/diagnóstico por imagem , Neuralgia do Trigêmeo/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Face/inervação , Face/fisiopatologia , Dor Facial/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Radiografia , Fatores de Tempo , Resultado do Tratamento , Procedimentos Cirúrgicos VascularesRESUMO
Neuropathic pain, caused or initiated by a primary lesion in the peripheral or central nervous system, can result in a dramatic reduction in the patient's quality of life. The expression neuropathic pain covers a heterogeneous group of conditions, including peripheral neuropathy, complex regional pain syndrome, trigeminal neuralgia and central pain. Neuropathic pain poorly responds to conventional analgesics. However, with appropriate therapy, a significant proportion of patients experience a substantial pain reduction. We present here an evidence-based review of the options for the treatment of neuropathic pain syndromes. Consideration is given to the mechanisms of action, numbers needed to treat (NNT), the recommended doses and the most frequent side-effects of the drugs for which consistent support has been found for treatment of these pain conditions.
Assuntos
Analgésicos/uso terapêutico , Medicina Baseada em Evidências , Neuralgia/tratamento farmacológico , Humanos , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
In migraine and other primary headaches there is a strong vascular component. Besides the trigeminovascular components some of the associated symptoms point to the involvement of brain stem regions. The central limb of the trigeminal vascular pathway is its projection to the trigeminal nucleus caudalis (TNC) and to the C1-C2 levels of the spinal cord. The aim of the present study was to demonstrate the occurrence of some neurotransmitters in these regions in man. In both the TNC and in the Rexed's laminae I and II of the dorsal horns at the C1 and C2 levels there were numerous substance P immunoreactive fibres. Fibres containing calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide (PACAP) were moderately dense in number. Fibres containing vasoactive intestinal peptide (VIP) or nitric oxide synthase (NOS) were not seen in the TNC or at the C1 and C2 levels of the spinal cord.
Assuntos
Neuropeptídeos/metabolismo , Medula Espinal/metabolismo , Núcleo Inferior Caudal do Nervo Trigêmeo/metabolismo , Adulto , Idoso , Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Vértebras Cervicais , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Substância P/metabolismo , Peptídeo Intestinal Vasoativo/metabolismoRESUMO
Visual disturbances are frequent symptoms in migraine. Since there is a possibility of separate damage in the magno- or parvo-cellular visual pathway in migraine patients, we performed a study including the measurement of static and dynamic spatial contrast sensitivity on 15 patients suffering from migraine without aura under photopic and scotopic conditions. Fifteen healthy volunteers without primary headache served as controls. The results revealed a marked decrease in contrast sensitivity at low spatial frequencies in the migraine patients. Spatial contrast sensitivity demonstrated some lateralization, as the sensitivity to low spatial frequencies obtained through separate eyes showed significantly larger side-differences in migraine patients than in control subjects. These findings suggest that the mechanisms responsible for vision at low spatial frequencies are impaired in migraine patients. This might indicate impaired function of the magnocellular pathways in this condition.
Assuntos
Sensibilidades de Contraste , Enxaqueca sem Aura/fisiopatologia , Percepção Espacial , Adulto , Análise de Variância , Adaptação à Escuridão , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
5-Hydroxytryptamine (5-HT) is implicated in migraine and agonist directed against 5-HT(1B) and 5-HT(1D) receptors are commonly used as effective therapies. The antimigraine mechanisms involve the inhibition of intracranial sensory neuropeptide release. In order to determine which 5-HT(1) receptor subtypes are involved we have by immunocytochemistry examined the distribution of 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglia, and addressed which of them colocalize with calcitonin gene-related peptide (CGRP), substance P (SP) or nitric oxide synthase (NOS). We detected that 5-HT(1D) receptor immunoreactivity (i.r.) was predominantly expressed in medium-sized cells (86% of positive cells, 30-60 microm). About 9% of the 5-HT(1D) receptor i.r. cells were large in size (> 60 microm) and 5% were small in size (< 30 microm). In a similar pattern, 5-HT(1B) receptor i.r. was mainly expressed in medium-sized cells (81% in 30-60 microm, 15% in > 60 microm and 4% in < 30 microm). Double immunostaining was used to determine whether the 5-HT(1B) or 5-HT(1D) receptor immunoreactive cells co-localized with either CGRP, SP or NOS. Thus, 89% of the CGRP i.r. cells expressed 5-HT(1D) receptor i.r. and 65% of the CGRP positive cells were 5-HT(1B) receptor positive. Most of the 5-HT(1D) (95%) and the 5-HT(1B) (94%) receptor i.r. cells showed SP immunostaining and 83% of 5-HT(1D) receptor and 86% of 5-HT(1B) receptor i.r. cells contained NOS. In conclusion, both 5-HT(1B) and 5-HT(1D) receptors are expressed in the human trigeminal ganglion and they are mainly localized in medium-sized cells and they seem to colocalize with CGRP, SP and NOS.
Assuntos
Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Neurônios Aferentes/metabolismo , Óxido Nítrico Sintase/metabolismo , Receptores de Serotonina/metabolismo , Substância P/metabolismo , Gânglio Trigeminal/metabolismo , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Neurônios Aferentes/citologia , Óxido Nítrico/metabolismo , Receptor 5-HT1B de Serotonina , Receptor 5-HT1D de Serotonina , Serotonina/metabolismo , Gânglio Trigeminal/citologiaRESUMO
Evidence from animals and humans suggests that brainstem nuclei such as the raphe nuclei, the locus coeruleus (LC) and the periaqueductal grey matter (PAG), are involved in the pathophysiology of migraine. In order to understand possible neurotransmitters involved we have, by means of indirect immunocytochemistry, analysed these regions for the occurrence and distribution of calcitonin gene-related peptide (CGRP), substance P (SP), pituitary adenylate-cyclase activating peptide (PACAP) and vasoactive intestinal polypeptide (VIP). CGRP-immunoreactive (-ir) cell bodies, but no fibres, were found to occur in high numbers, constituting 80% of all nerve cell bodies in the LC. A smaller number of these nerve cell bodies (40%) in the LC proved to be PACAP-ir. The LC neurones also stored the vesicular monoamine transporter (VMAT)- and the C-terminal flanking peptide of neuropeptide Y (C-PON)-ir, illustrating their adrenergic nature. Double immunostaining revealed that all VMAT-and C-PON-containing neurones, in addition, stored CGRP. Immunoreactive cell bodies were not seen in the nucleus raphe magnus (NRM) or PAG. Numerous SP-ir nerve fibres were observed in the NRM, the LC and the PAG. Few PACAP-ir nerve fibres were detected in the PAG and few VIP-ir nerve fibres were seen in the NRM and the PAG.
Assuntos
Tronco Encefálico/patologia , Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Transtornos de Enxaqueca/patologia , Neuropeptídeos/metabolismo , Adulto , Idoso , Feminino , Humanos , Locus Cerúleo/patologia , Masculino , Pessoa de Meia-Idade , Neuropeptídeo Y/metabolismo , Fragmentos de Peptídeos/metabolismo , Substância Cinzenta Periaquedutal/patologia , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Núcleos da Rafe/patologia , Substância P/metabolismo , Peptídeo Intestinal Vasoativo/metabolismoRESUMO
Sodium azide (20mg/kgsc), given for a maximum of 3 days to rats, significantly decreased the alpha-tocopherol concentrations in the cortex on day 2 and in the striatum on day 3. In these brain regions the oxidized glutathione values showed 30 to 36% (statistically not significant) elevation on day 3. Reduced glutathione levels were not altered. The observations suggest an important role for alpha-tocopherol in the defense against azide induced free radicals probably including NO and lipid peroxide radicals.
Assuntos
Córtex Cerebral/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Radicais Livres/metabolismo , Neostriado/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Azida Sódica/farmacologia , Vitamina E/biossíntese , Animais , Córtex Cerebral/metabolismo , Córtex Cerebral/fisiopatologia , Transporte de Elétrons/efeitos dos fármacos , Transporte de Elétrons/fisiologia , Metabolismo Energético/efeitos dos fármacos , Metabolismo Energético/fisiologia , Ácido Glutâmico/metabolismo , Glutationa/biossíntese , Glutationa/efeitos dos fármacos , Peroxidação de Lipídeos/efeitos dos fármacos , Peroxidação de Lipídeos/fisiologia , Masculino , Neostriado/metabolismo , Neostriado/fisiopatologia , Doenças Neurodegenerativas/tratamento farmacológico , Doenças Neurodegenerativas/metabolismo , Doenças Neurodegenerativas/fisiopatologia , Óxido Nítrico/biossíntese , Estresse Oxidativo/fisiologia , Ratos , Ratos Sprague-Dawley , Receptores de N-Metil-D-Aspartato/efeitos dos fármacos , Receptores de N-Metil-D-Aspartato/metabolismo , Frações Subcelulares/efeitos dos fármacos , Frações Subcelulares/metabolismoRESUMO
The supratentorial cerebral dura of the albino rat is equipped with a rich sensory innervation both in the connective tissue and around blood vessels, which includes nociceptive axons and their terminals; these display intense calcitonin gene-related peptide (CGRP) immunoreactivity. Stereotactic electrical stimulation of the trigeminal (Gasserian) ganglion, regarded as an experimental migraine model, caused marked increase and disintegration of club-like perivascular CGRP-immunopositive nerve endings in the dura mater and induced an apparent increase in the lengths of CGRP-immunoreactive axons. Intravenous administration of sumatriptan or eletriptan, prior to electrical stimulation, prevented disintegration of perivascular terminals and induced accumulation of CGRP in terminal and preterminal portions of peripheral sensory axons. Consequently, immunopositive terminals and varicosities increased in size; accumulation of axoplasmic organelles resulted in the "hollow" appearence of numerous varicosities. Since triptans exert their anti-migraine effect by virtue of agonist action on 5-HT(1D/B) receptors, we suggest that these drugs prevent the release of CGRP from perivascular nerve terminals in the dura mater by an action at 5-HT(1D/B) receptors. Nitroglycerine (NitroPOHL), given subcutaneously to rats, induces increased beading of nitric oxide synthase (NOS)-immunoreactive nerve fibers in the supratentorial cerebral dura mater, and an apparent increase in the number of NOS-immunoreactive nerve fibers in the dural areas supplied by the anterior and middle meningeal arteries, and the sinus sagittalis superior. Structural alterations of nitroxidergic axons innervating blood vessels of the dura mater support the idea that nitric oxide (NO) is involved in the induction of headache, a well-known side effect of coronary dilator agents.
Assuntos
Dura-Máter/metabolismo , Transtornos de Enxaqueca/metabolismo , Fibras Nervosas/metabolismo , Neuropeptídeos/metabolismo , Óxido Nítrico Sintase/metabolismo , Animais , Capilares/inervação , Capilares/ultraestrutura , Dura-Máter/irrigação sanguínea , Dura-Máter/ultraestrutura , Estimulação Elétrica , Feminino , Imuno-Histoquímica , Indóis/farmacologia , Masculino , Microscopia Eletrônica , Terminações Nervosas/irrigação sanguínea , Terminações Nervosas/fisiopatologia , Fibras Nervosas/efeitos dos fármacos , Fibras Nervosas/ultraestrutura , Doadores de Óxido Nítrico/farmacologia , Óxido Nítrico Sintase/antagonistas & inibidores , Nitroglicerina/farmacologia , Pirrolidinas/farmacologia , Ratos , Ratos Wistar , Agonistas do Receptor de Serotonina/farmacologia , Sumatriptana/farmacologia , Gânglio Trigeminal/fisiopatologia , Gânglio Trigeminal/ultraestrutura , Triptaminas , Vasoconstritores/farmacologiaRESUMO
The cerebral circulation is innervated by calcitonin gene-related peptide (CGRP) containing fibers originating in the trigeminal ganglion. During a migraine attack, there is a release of CGRP in conjunction with the head pain, and triptan administration abolishes both the CGRP release and the pain at the same time. In the search for a novel treatment of migraine, a non-peptide CGRP antagonist has long been sought. Here, we present data on a human cell line and human and guinea-pig isolated cranial arteries for such an antagonist, Compound 1 (4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid [1-(3,5-dibromo-4-hydroxy-benzyl)-2-oxo-2-(4-phenyl-piperazin-1-yl)-ethyl]-amide). On SK-N-MC cell membranes, radiolabelled CGRP binding was displaced by both CGRP-(8-37) and Compound 1, yielding pK(i) values of 8.9 and 7.8, respectively. Functional studies with SK-N-MC cells showed that CGRP-induced cAMP production was antagonised by both CGRP-(8-37) and Compound 1 with pA(2) values of 7.8 and 7.7, respectively. Isolated human and guinea pig cerebral arteries were studied with a sensitive myograph technique. CGRP induced a concentration-dependent relaxation in human cerebral arteries which was antagonized by both CGRP-(8-37) and Compound 1 in a competitive manner. In guinea pig basilar arteries, CGRP-(8-37) antagonised the CGRP-induced relaxation while Compound 1 had a weak blocking effect. The clinical studies of non-peptide CGRP antagonists are awaited with great interest.